Many Sacklers, Many Trusts: Why Purdue Pharma Wants a Settlement
For Purdue Pharma LP, the rationale behind a proposed $4.3 billion settlement with the members of the billionaire Sackler family that own the company comes down to uncertainty. The bankrupt OxyContin maker -- as well as creditors seeking to hold Purdue and its owners accountable for the opioid crisis -- could use wide-ranging legal theories to try to extract billions of dollars from members of the Sackler family. But the endeavor would be convoluted, expensive, and could fail entirely, Purdue’s lawyers argue in new bankruptcy court papers, Bloomberg News reported. Their argument comes as Purdue is seeking approval to collect creditor votes on its bankruptcy plan at a hearing scheduled for this week. Certain details of the settlement with its owners aren’t yet finalized, and more than 20 U.S. states still don’t support the plan. The Sackler family is large, fragmented, and scattered across the globe. Its wealth -- recently estimated at $11 billion -- is concentrated in “dozens” of trusts in the U.S. and abroad, including islands off the coast of France, according to court papers. To get to the money, the company and others would “have to separately sue, prevail, and collect against each of these individuals, and expend considerable resources in the process without any guarantee of success,” Purdue’s attorneys wrote.
